IRX 2 clinical trials
Also written IRX-2.
- studies test it
- 8
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses IRX 2 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 6
City of Hope Medical Center (2) · Brooklyn ImmunoTherapeutics, LLC (2) · Providence Health & Services (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · University of Southern California (1) · Emory University (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test IRX 2.
- Mar 2027IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerPhase 1 · City of Hope Medical Center
Studies
Open first, then newest update. How each study uses IRX 2 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction CancerCompletedPhase 1/2City of Hope Medical CenterNCT03918499Written as Cytokine-based Biologic Agent IRX-2
- IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver CancerActive, not recruitingPhase 1City of Hope Medical CenterNCT03655002Written as Cytokine-based Biologic Agent IRX-2
- Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast CancerActive, not recruitingPhase 2Providence Health & ServicesNCT04373031Written as IRX 2
- IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3TerminatedPhase 2University of Southern CaliforniaNCT03267680Written as IRX-2
- IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral CavityCompletedPhase 2Brooklyn ImmunoTherapeutics, LLCNCT02609386Written as IRX-2
- IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid TumorsCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT03758781Written as IRX 2
- A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck CancerCompletedPhase 2Brooklyn ImmunoTherapeutics, LLCNCT00210470Written as IRX-2
- Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal CancerWithdrawnPhase 1Emory UniversityNCT03575234Written as IRX-2
Codes
What other systems call IRX 2 · ClinicalTrials.gg INT004102
- UNII (FDA) ZDR4QSJ43FIRX-2One source FDA
- NCI Thesaurus C53396Cytokine-based Biologic Agent IRX-2One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ZDR4QSJ43F | IRX-2 | One source FDA |
| NCI Thesaurus | C53396 | Cytokine-based Biologic Agent IRX-2 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.